Tags : Injectable Regimen

ViiV Healthcare Initiates CUSTOMIZE Study of Dual-Drug Injectable Regimen for

Shots: The CUSTOMIZE study will evaluate the two-drug regimen consisting ViiV’s Cabotegravir and Janssen’s Edurant (rilpivirine) in patients with HIV with suppressed viral load and no resistance to cabotegravir or rilpivirine In Apr’2019, the US FDA has accepted NDA filing of long-acting dual-drug injectable regimen and has granted PR to NDA with its expected PDUFA […]Read More